Report Detail
Global Anti-VEGF Medicine Market Growth 2022-2028
- RnM4478705 |
- 05 August, 2022 |
- Global |
- 95 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
The global market for Anti-VEGF Medicine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Anti-VEGF Medicine players cover Faricimab, Bayer (Regeneron), Brolucizumab, Kanghong Pharmaceutical and Santen. etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Anti-VEGF Medicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Anti-VEGF Medicine market, with both quantitative and qualitative data, to help readers understand how the Anti-VEGF Medicine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Anti-VEGF Medicine market and forecasts the market size by Type (Single Target (Ranibizumab, etc.) and Multiple Targets (Aflibercept, Conbercept, etc.),), by Application (Hospital, Eye Clinic and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Single Target (Ranibizumab, etc.)
Multiple Targets (Aflibercept, Conbercept, etc.)
Segmentation by application
Hospital
Eye Clinic
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Faricimab
Bayer (Regeneron)
Brolucizumab
Kanghong Pharmaceutical
Santen
Chapter Introduction
Chapter 1: Scope of Anti-VEGF Medicine, Research Methodology, etc.
Chapter 2: Executive Summary, global Anti-VEGF Medicine market size (sales and revenue) and CAGR, Anti-VEGF Medicine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Anti-VEGF Medicine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Anti-VEGF Medicine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Anti-VEGF Medicine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Faricimab, Bayer (Regeneron), Brolucizumab, Kanghong Pharmaceutical and Santen, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Anti-VEGF Medicine Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Anti-VEGF Medicine by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Anti-VEGF Medicine by Country/Region, 2017, 2022 & 2028
- 2.2 Anti-VEGF Medicine Segment by Type
- 2.2.1 Single Target (Ranibizumab, etc.)
- 2.2.2 Multiple Targets (Aflibercept, Conbercept, etc.)
- 2.3 Anti-VEGF Medicine Sales by Type
- 2.3.1 Global Anti-VEGF Medicine Sales Market Share by Type (2017-2022)
- 2.3.2 Global Anti-VEGF Medicine Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Anti-VEGF Medicine Sale Price by Type (2017-2022)
- 2.4 Anti-VEGF Medicine Segment by Application
- 2.4.1 Hospital
- 2.4.2 Eye Clinic
- 2.4.3 Other
- 2.5 Anti-VEGF Medicine Sales by Application
- 2.5.1 Global Anti-VEGF Medicine Sale Market Share by Application (2017-2022)
- 2.5.2 Global Anti-VEGF Medicine Revenue and Market Share by Application (2017-2022)
- 2.5.3 Global Anti-VEGF Medicine Sale Price by Application (2017-2022)
3 Global Anti-VEGF Medicine by Company
- 3.1 Global Anti-VEGF Medicine Breakdown Data by Company
- 3.1.1 Global Anti-VEGF Medicine Annual Sales by Company (2020-2022)
- 3.1.2 Global Anti-VEGF Medicine Sales Market Share by Company (2020-2022)
- 3.2 Global Anti-VEGF Medicine Annual Revenue by Company (2020-2022)
- 3.2.1 Global Anti-VEGF Medicine Revenue by Company (2020-2022)
- 3.2.2 Global Anti-VEGF Medicine Revenue Market Share by Company (2020-2022)
- 3.3 Global Anti-VEGF Medicine Sale Price by Company
- 3.4 Key Manufacturers Anti-VEGF Medicine Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Anti-VEGF Medicine Product Location Distribution
- 3.4.2 Players Anti-VEGF Medicine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Anti-VEGF Medicine by Geographic Region
- 4.1 World Historic Anti-VEGF Medicine Market Size by Geographic Region (2017-2022)
- 4.1.1 Global Anti-VEGF Medicine Annual Sales by Geographic Region (2017-2022)
- 4.1.2 Global Anti-VEGF Medicine Annual Revenue by Geographic Region
- 4.2 World Historic Anti-VEGF Medicine Market Size by Country/Region (2017-2022)
- 4.2.1 Global Anti-VEGF Medicine Annual Sales by Country/Region (2017-2022)
- 4.2.2 Global Anti-VEGF Medicine Annual Revenue by Country/Region
- 4.3 Americas Anti-VEGF Medicine Sales Growth
- 4.4 APAC Anti-VEGF Medicine Sales Growth
- 4.5 Europe Anti-VEGF Medicine Sales Growth
- 4.6 Middle East & Africa Anti-VEGF Medicine Sales Growth
5 Americas
- 5.1 Americas Anti-VEGF Medicine Sales by Country
- 5.1.1 Americas Anti-VEGF Medicine Sales by Country (2017-2022)
- 5.1.2 Americas Anti-VEGF Medicine Revenue by Country (2017-2022)
- 5.2 Americas Anti-VEGF Medicine Sales by Type
- 5.3 Americas Anti-VEGF Medicine Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Anti-VEGF Medicine Sales by Region
- 6.1.1 APAC Anti-VEGF Medicine Sales by Region (2017-2022)
- 6.1.2 APAC Anti-VEGF Medicine Revenue by Region (2017-2022)
- 6.2 APAC Anti-VEGF Medicine Sales by Type
- 6.3 APAC Anti-VEGF Medicine Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
7 Europe
- 7.1 Europe Anti-VEGF Medicine by Country
- 7.1.1 Europe Anti-VEGF Medicine Sales by Country (2017-2022)
- 7.1.2 Europe Anti-VEGF Medicine Revenue by Country (2017-2022)
- 7.2 Europe Anti-VEGF Medicine Sales by Type
- 7.3 Europe Anti-VEGF Medicine Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Anti-VEGF Medicine by Country
- 8.1.1 Middle East & Africa Anti-VEGF Medicine Sales by Country (2017-2022)
- 8.1.2 Middle East & Africa Anti-VEGF Medicine Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Anti-VEGF Medicine Sales by Type
- 8.3 Middle East & Africa Anti-VEGF Medicine Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Medicine
- 10.3 Manufacturing Process Analysis of Anti-VEGF Medicine
- 10.4 Industry Chain Structure of Anti-VEGF Medicine
11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Anti-VEGF Medicine Distributors
- 11.3 Anti-VEGF Medicine Customer
12 World Forecast Review for Anti-VEGF Medicine by Geographic Region
- 12.1 Global Anti-VEGF Medicine Market Size Forecast by Region
- 12.1.1 Global Anti-VEGF Medicine Forecast by Region (2023-2028)
- 12.1.2 Global Anti-VEGF Medicine Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Anti-VEGF Medicine Forecast by Type
- 12.7 Global Anti-VEGF Medicine Forecast by Application
13 Key Players Analysis
- 13.1 Faricimab
- 13.1.1 Faricimab Company Information
- 13.1.2 Faricimab Anti-VEGF Medicine Product Offered
- 13.1.3 Faricimab Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 Faricimab Main Business Overview
- 13.1.5 Faricimab Latest Developments
- 13.2 Bayer (Regeneron)
- 13.2.1 Bayer (Regeneron) Company Information
- 13.2.2 Bayer (Regeneron) Anti-VEGF Medicine Product Offered
- 13.2.3 Bayer (Regeneron) Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 Bayer (Regeneron) Main Business Overview
- 13.2.5 Bayer (Regeneron) Latest Developments
- 13.3 Brolucizumab
- 13.3.1 Brolucizumab Company Information
- 13.3.2 Brolucizumab Anti-VEGF Medicine Product Offered
- 13.3.3 Brolucizumab Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 Brolucizumab Main Business Overview
- 13.3.5 Brolucizumab Latest Developments
- 13.4 Kanghong Pharmaceutical
- 13.4.1 Kanghong Pharmaceutical Company Information
- 13.4.2 Kanghong Pharmaceutical Anti-VEGF Medicine Product Offered
- 13.4.3 Kanghong Pharmaceutical Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 Kanghong Pharmaceutical Main Business Overview
- 13.4.5 Kanghong Pharmaceutical Latest Developments
- 13.5 Santen
- 13.5.1 Santen Company Information
- 13.5.2 Santen Anti-VEGF Medicine Product Offered
- 13.5.3 Santen Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.5.4 Santen Main Business Overview
- 13.5.5 Santen Latest Developments
14 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Anti-VEGF Medicine. Industry analysis & Market Report on Anti-VEGF Medicine is a syndicated market report, published as Global Anti-VEGF Medicine Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Anti-VEGF Medicine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
